Physician profile

Trevor Spence

Nurse Practitioner · Caldwell, ID

NPI 1669063384

$828.66

in general payments reported to CMS, 2019-2025

5 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$828.66

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Stryker Corporation $554.73 2023-2024 Blueprint Patient Specific Instrumentation, Tornier Perform Reversed Glenoid, Mako
Zimmer Biomet Holdings, INC. $199.01 2023 Trabecular Metal, Comprehensive Shoulder System, Rosa
Ferring Pharmaceuticals INC. $37.16 2023-2024 Euflexxa
Bioventus LLC $21.81 2024 Exogen Ultrasound Bone Healing System
Avanos Medical $15.95 2023 On-Q* Pump and Accessories

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Trevor Spence

$828.66

in general payments reported 2019-2025

Years
2023-2024
Top company
Stryker Corporation

https://glasscript.com/doctor/10500875/trevor-spence

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.